Navigation Links
Eight-Year Melanoma Remission is Among Early Cancer Treatment Results
Date:7/13/2008

NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment already has benefited several individuals with aggressive malignancies. Offered through NeoPlas Innovation, this regimen has arrested or eradicated tumors in more than 80% of initial patients. Director of Research Dr. Stephen Cantrell emphasized that human testing is in its early stages, but added, "These results have surprised us. This is far beyond what currently available standard treatments achieve."

Melanoma, a deadly form of malignant skin cancer, is among the diseases targeted to date. The first person treated with the investigative protocol had stage 4 melanoma and a life expectancy of eight weeks. He experienced a complete response and remains disease-free eight years later. While not all results have been this dramatic, each NeoPlas melanoma patient has had results significantly better than those with standard therapy. Eradication of tumors or long-term stability has occurred in most patients; others have seen a substantial slowing of progression.

The new protocol incorporates a unique combination of FDA-approved drugs used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous, single-drug studies.

The NeoPlas treatment disables certain abnormal cellular processes many of the aggressive malignancies share. Based on experience and relevant lab research to date, staff members expect the best results for: melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. The regimen is not expected to have significant benefit against brain tumors.

The most notable side effect is fatigue. Most patients ne
'/>"/>

SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
2. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
3. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
4. Patients Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
6. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
7. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
8. Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
11. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Rescheduling of hydrocodone combination products (HCPs) will ... according to a new primary market research study ... research and consultation exclusively in the area of ... In August, the DEA ... from Schedule III to Schedule II status. This ...
(Date:10/22/2014)... 22, 2014 Investor-Edge has initiated ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,419.48, up 2.40%, the ...
(Date:10/22/2014)... 2014  Charlene Vernak, RPh, of Vernak Farms Pharmacy ... was awarded the George Roentsch Scholarship by the Professional ... in Houston during PCCA,s International ... annually to an independent pharmacist and PCCA member who ... Roentsch , a well-known pharmacist in the compounding community. ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2
... Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta- based ... entered into a $10 million common,stock purchase agreement ... investor., The Company may sell up to ... from time to time over a 25-month period ...
... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) announced today ... Food and Drug Administration ("FDA") of an,Investigational Device ... SEPET(TM), Arbios, extracorporeal (outside the body) liver assist,device ... from,chronic liver disease., "We are pleased to ...
Cached Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... responding to the devastation across Greece caused by this ... series of crisis map products based on satellite acquisitions ... assessment efforts following the activation of the International Charter ... people were killed and thousands left homeless in the ...
... 21 Baxa Corporation, a leading,provider of systems ... announces the addition of two new international product,distributors. ... Colombia and Pentafarma & Co. in The Dominican ... reach and expand product promotion in South,America and ...
... from DCM and Split Rock Partners, PALO ALTO, ... of its website. Caring.com will offer original "how,to" guides, ... and a community of people in caring situations, to ... million adults who are,caring for an aging relative in ...
... scientific peer review, will gather in Helsinki on 27 September ... from the fourth and final Call of the European Young ... to create teams in Europe to focus on cutting-edge science. ... from around the world to create their own research teams ...
... drugs plus insulin works best, researchers say , , FRIDAY, ... tell which insulin-plus-drug regimen might best control type 2 ... the three strategies tested coming out on top. , ... in the study can be recommended" as being superior ...
... Waltham, MA -- Brandeis neuroscientist Gina Turrigiano has been ... Award, a five-year grant totaling $2.5 million. She is ... competitive award. , According to NIH, the award ... who propose pioneering approaches to major challenges in biomedical ...
Cached Medicine News:Health News:Greeks get space-based help in wake of deadly fires 2Health News:Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 2Health News:New Resource for Taking Care of Aging Parents Available in Beta 3Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 2Health News:2007 EURYI: 20 researchers to receive Nobel Prize-sized awards in Helsinki 3Health News:No Clear Winner in Diabetes Treatment Trial 2Health News:No Clear Winner in Diabetes Treatment Trial 3
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
Inquire...
Inquire...
Medicine Products: